Conclusion. The single-trough method performed similarly to the more laborious P/T method. No patient would have received a dose adjustment based on the two different AUC estimation methods. The single-trough method may represent a resource and workflow conscious AUC estimation method for patients meeting population assumptions.

Disclosures. All Authors: No reported disclosures

1108. Evaluation of Vancomycin Dosing in Adolescents
Ashley L. Weaver, PharmD1; Genene A. Wilson, PharmD2; Emily Belanski, PharmD, BCPS3; Allison Nelson, PharmD1; Madan Kumar DO1; Pulak Bhagat, PharmD, BCPS3; 1University of Chicago Medicine, Indianapolis, Indiana, Indiana; 2Dell Children’s Medical Center, Austin, Texas; 3University of Chicago Medicine, Chicago, Illinois;
4University of Chicago Medicine Comer Children’s Hospital, Geneva, IL, 5University of Chicago, Chicago, IL
Session: P-62. PK/PD Studies

Background. Febrile vancomycin dosing varies based on age and renal function. Recent literature suggests previously recommended doses of 45-60 mg/kg/day may be insufficient to achieve an AUC/MIC ratio of 400-600 mg-hr/L and higher doses of at least 60 mg/kg/day may be required. However, data to guide dosing in adolescents is limited.

Methods. A single-center, retrospective chart review of patients aged 12 to 18 years who received vancomycin and had therapeutic drug monitoring (TDM) performed between July 2017 to June 2020 were included. The primary endpoint was the median total daily dose (TDD) of vancomycin required to achieve therapeutic serum concentrations. Secondary endpoints were to characterize how factors such as age, weight, trough versus AUC monitoring, malignancy, and trauma may influence dosing. The safety endpoint was the development of acute kidney injury (AKI).

Results. 130 vancomycin courses in 86 patients were included. Baseline characteristics are presented in Table 1. Of the 130 vancomycin courses, 50 courses (38%) achieved therapeutic serum concentrations at a median TDD of 49.8 mg/kg/day (IQR 42-59.4). This was not statistically different from the sub- or supra-therapeutic groups (p=0.22).

Conclusion. To achieve therapeutic levels, adolescents 12 to 14 years old need higher empiric doses of 60 mg/kg/day compared to 45 mg/kg/day in 15 to 18 years old. Obese patients, however, may require lower TDD than underweight, healthy, and overweight patients. Patients that receive AUC versus trough monitoring may also require lower TDD to achieve therapeutic concentrations. More data is needed to further evaluate our findings.

Disclosures. All Authors: No reported disclosures

1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)
Abigail K. Kois, PharmD1; Jason A. Gluck, DO2; David P. Nicolau, PharmD3; Joseph L. Kuti, PharmD4; Hartford Hospital, Hartford, Connecticut; 1Hartford Healthcare, Hartford, Connecticut; 3Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut
Session: P-62. PK/PD Studies

Background. ECMO is a life-saving tool utilized in critically ill patients that require respiratory and/or cardiac support. ECMO may also affect the pharmacokinetics (PK) of certain medications, including some antibiotics. Cefepime is a widely used antibiotic in this population due to its broad spectrum activity but limited data are available to guide dosing in patients requiring ECMO.

Methods. This was a prospective, single-center study of 6 critically ill adult patients requiring ECMO and receiving cefepime 2g q8h as a 3h infusion. After obtaining informed consent, 4-6 blood samples within the dosing interval were collected to determine cefepime concentrations. Population PK was conducted in Pmetrics using R. Final MAP Bayes parameters were estimated to use simulated free time above MIC (%T >MIC) for various cefepime dosing regimens. The target pharmacodynamic exposure was 70% T >MIC.

Results. Patients were between 31-62 years old; 4/6 (66.7%) were on veno-venous (VV) ECMO and 2 veno-arterio (VA) ECMO. Two patients required continuous venovenous hemofiltration (CVVHDF) while the other 4 had a CrCl between 92-199 ml/min. A two compartment model fitted the data better than a one compartment model. Median (range) final population PK parameters were: clearance (CL) 9.8 L/h (7.6-33.1); volume of central compartment (V1) 6.9 L (4.7-49.8); and intercompartment transfer constant (k21) 1.48 h-1 (1.24-2.29); and k12 1.49 h-1 (0.75-1.71). The 2g q8h (3h infusion) regimen resulted in target exposure in all 6 patients achieving at least 16 mg/L. A standard 2g q12h (0.5h infusion) regimen would have resulted in 5/6 patients achieving 70% T >MIC at 8 mg/L and 1/6 at 16 mg/L.

Conclusion. These are the first data describing cefepime PK and exposure attainment in critically ill patients receiving ECMO. Cefepime 2g q8h (3h infusion) achieved target pharmacodynamic exposure up to the susceptibility breakpoint of 8 mg/L in all 6 patients, including 2 concomitant CVVHDF. Additional studies are warranted to define cefepime PK in patients on ECMO across a robust range of CrCl to guide dosing.

Disclosures. David P. Nicolau, PharmD, Abbvie, Cepheid, Merck, Paratek, Pfizer, stockholder, Shionogi, Tetrabaphse (Other Financial or Material Support, I have been a consultant, speakers bureau member, or have received research funding from the above listed companies.) Joseph L. Kuti, PharmD, Allergan (Research Grant or Support) (Scientific Research Study Investigator) (Consultant) (Research Grant or Support) (Speaker's Bureau) BioMerieux (Consultant, Research Grant or Support, Speaker’s Bureau)Contrafect (Scientific Research Study Investigator) (Consultant) (Research Grant or Support)Paratek (Speaker’s Bureau) Roche Diagnostics (Research Grant or Support)Shionogi (Scientific Research Study Investigator) Summit (Scientific Research Study Investigator)

1110. In Vivo Pharmacodynamics of Vancomycin Against Staphylococci in Young Infants
Amanda Gwee, MBBS, FRACP, DTMI, PhD1; Stephen Duffull, PhD2; Derek Zhu, PhD3; 1The Royal Children's Hospital, Melbourne, Victoria, Parkville, Victoria, Australia; 2University of Otago, Dunedin, Otago, New Zealand
Session: P-62. PK/PD Studies

Background. Coagulase-negative staphylococci are the predominant pathogen causing late onset sepsis in young infants, however, the pharmacodynamic target for vancomycin therapy is unknown. This study aimed to determine the pharmacodynamic target of vancomycin in young infants with staphylococcal infections.

Results. All data presented as median (IQR)

Conclusion. The single-trough method performed similarly to the more laborious P/T method. No patient would have received a dose adjustment based on the two different AUC estimation methods. The single-trough method may represent a resource and workflow conscious AUC estimation method for patients meeting population assumptions.